Bayer and Vanderbilt University Medical Center Announce Five-Year Collaboration to Advance Cardiovascular and Kidney Disease Treatments
Bayer and Vanderbilt University Medical Center (VUMC) entered a five-year strategic collaboration on January 20, 2026, to advance therapies from early target identification through Investigational New Drug (IND) application.
Initial focus is on cardiovascular and kidney diseases, areas with significant unmet medical needs.
The partnership combines Bayer's drug discovery and translational science expertise with VUMC's preclinical/clinical knowledge and access to large-scale datasets like the BioVU collection of DNA and plasma.
Aims to accelerate discovery using real-world and genetic data for precision-medicine approaches.
Quotes from Bayer's Juergen Eckhardt and VUMC's Ken Holroyd highlight commitment to innovative treatments and data-driven insights.